Abstract

264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
LBA12_PR - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
...
Annals of Oncology | VOL. 30
, et. al. ...
01 Oct 2019
LBA8 - PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
A Kohlmann ... N Agarwal
Annals of Oncology | VOL. 30
A Kohlmann, et. al.A Kohlmann ... N Agarwal
01 Nov 2019
1542P - Safety of lorlatinib in subgroups of patients from a phase I/II trial
E Felip ... G Peltz
Annals of Oncology | VOL. 30
E Felip, et. al.E Felip ... G Peltz
01 Oct 2019
LBA21 - KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
A Gonçalves ... X Zhou
Annals of Oncology | VOL. 30
A Gonçalves, et. al.A Gonçalves ... X Zhou
01 Oct 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Re: Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]. Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4
Elio Mazzone ... Francesco Montorsi
Annals of Oncology | VOL. -
Elio Mazzone, et. al.Elio Mazzone ... Francesco Montorsi
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
View more papers